Catalyst Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:CPRX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
20 Aug 24	SellUS$3,052,900	Steven Miller	Individual	150,000	US$20.59
09 Aug 24	SellUS$111,710	Jeffrey Del Carmen	Individual	6,058	US$18.44
07 Jun 24	SellUS$121,184	Jeffrey Del Carmen	Individual	7,541	US$16.07
03 Jun 24	SellUS$86,949	Molly Harper	Individual	5,333	US$16.30
27 Mar 24	SellUS$411,000	Brian Elsbernd	Individual	25,000	US$16.44

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CPRX?
Owner Type	Number of Shares	Ownership Percentage
State or Government	48,394	0.0406%
Hedge Funds	6,229,634	5.22%
Individual Insiders	7,564,303	6.34%
General Public	14,361,038	12%
Institutions	91,070,067	76.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 62.27% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15.9%	BlackRock, Inc.	19,017,491	US$455.7m	1.73%	0.01%
6.74%	The Vanguard Group, Inc.	8,040,978	US$192.7m	-0.73%	no data
5.22%	Deerfield Management Company, L.P. Series C	6,229,634	US$149.3m	-31.8%	2.49%
4.77%	State Street Global Advisors, Inc.	5,685,330	US$136.2m	-5.77%	no data
3.76%	Patrick McEnany	4,481,702	US$107.4m	0.08%	no data
2.53%	Dimensional Fund Advisors LP	3,018,789	US$72.3m	0.6%	0.01%
2.48%	Pacer Advisors, Inc.	2,955,508	US$70.8m	5.4%	0.15%
2.23%	Geode Capital Management, LLC	2,664,424	US$63.8m	-1.27%	no data
2.12%	Renaissance Technologies LLC	2,526,016	US$60.5m	16.1%	0.08%
2.04%	First Trust Advisors LP	2,428,973	US$58.2m	-1.78%	0.04%
1.69%	Royce & Associates, LP	2,021,105	US$48.4m	-6.52%	0.38%
1.21%	Morgan Stanley, Investment Banking and Brokerage Investments	1,439,286	US$34.5m	92.7%	no data
1.16%	Northern Trust Global Investments	1,383,800	US$33.2m	-0.21%	no data
1.07%	Boston Partners Global Investors, Inc.	1,275,267	US$30.6m	0%	0.02%
1.03%	T. Rowe Price Group, Inc.	1,234,383	US$29.6m	0.12%	no data
0.98%	Charles Schwab Investment Management, Inc.	1,167,743	US$28.0m	0%	no data
0.95%	Teachers Insurance and Annuity Association-College Retirement Equities Fund	1,131,770	US$27.1m	37.2%	0.01%
0.92%	Goldman Sachs Group, Investment Banking and Securities Investments	1,100,696	US$26.4m	59%	0.01%
0.89%	Jacobs Levy Equity Management Inc	1,057,390	US$25.3m	-21.2%	0.09%
0.87%	Kennedy Capital Management LLC	1,041,416	US$25.0m	-18.4%	0.5%
0.8%	LSV Asset Management	951,324	US$22.8m	8.86%	0.04%
0.78%	Steven Miller	935,996	US$22.4m	38.6%	no data
0.72%	Marshall Wace LLP	860,934	US$20.6m	-29.4%	0.03%
0.69%	Invesco Capital Management LLC	818,333	US$19.6m	14.1%	0.01%
0.67%	Mesirow Financial Investment Management, Inc.	800,798	US$19.2m	-14.3%	0.27%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/30 23:16
End of Day Share Price	2025/01/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Catalyst Pharmaceuticals, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Matthew Gerberry	BofA Global Research
Charles Duncan	Cantor Fitzgerald & Co.
Samantha Lynn Semenkow	Citigroup Inc